博济医药(300404.SZ)：卿芷软膏获得药物临床试验批准通知书

Core Viewpoint - The approval of "Qingzhi Ointment" by the National Medical Products Administration marks a significant advancement for the company in the field of traditional Chinese medicine, potentially opening new market opportunities for innovative herbal treatments [1] Group 1: Product Development - The product "Qingzhi Ointment" is a new formulation based on traditional Chinese medicine principles, specifically designed for the treatment of knee osteoarthritis with symptoms of wind-cold-dampness [1] - It is classified as a Class 1 innovative traditional Chinese medicine, indicating its status as a new prescription that has not been marketed domestically or internationally [1] Group 2: Regulatory Approval - The full subsidiary of the company, Guangzhou Boji New Drug Clinical Research Center Co., Ltd., has successfully obtained the Clinical Trial Approval Notice from the National Medical Products Administration for "Qingzhi Ointment" [1] - This regulatory approval is a critical step in the drug development process, allowing the company to proceed with clinical trials [1]